1st and only HAE treatment indicated for use in pediatrics. Learn more ►
Berinert on demand is an essential part of your treatment plan.

Help your patients take control with the only approved C1-INH treatment for acute HAE attacks in adult and pediatric patients.

Self-administered Berinert treats HAE at the first sign of an acute attack Berinert is the only on-demand C1 esterase inhibitor (C1-INH) approved for treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and pediatrics.

Berinert is approved for patient self-administration after proper training by a healthcare professional. The safety and efficacy of Berinert for prophylactic therapy have not been established.

On-demand treatment helps patients take control of their HAE.

On-demand means treating with Berinert at the first sign of an HAE attack, which can occur suddenly, frequently, and without warning. Patients might notice certain symptoms that signal the onset of an attack. These warning signs can prompt early treatment—and early treatment can help reduce the time to relief.

Many patients develop symptoms that signal the onset of an acute HAE attack. Such symptoms as tingling, paresthesias, erythematous rash, fatigue, malaise, nausea, vomiting, and abdominal pain have been described by patients with HAE. It is important to discuss these symptoms with your patients so they can learn to recognize the early signs of an attack, and treat promptly.1

Berinert uses weight-based dosing of 20 IU/kg body weight, which ensures an optimized dose of C1-INH during an attack.

In Clinical Trial

Berinert Median Time to Onset of Symptoms Relief Chart
  • Median time to onset of symptom relief is 48 minutes for abdominal or facial attack
  • Median time to onset of symptom relief is 15 minutes for laryngeal attack

Make on-demand therapy your first-line therapy for HAE

All patients should have an on-demand treatment plan, even if they are on prophylactic therapy. Current prophylactic therapies are not 100% effective and breakthrough attacks may occur. Even in cases where patients experience 2 to 4 attacks per month, patients may be able to better manage their HAE by treating each attack with Berinert at the first sign.11

In fact, the World Allergy Organization (WAO) recommends that:11

  • All attacks that result in debilitation or dysfunction and/or involve the face, the neck, or the abdomen should be considered for on-demand treatment.
  • Treatment of attacks affecting the upper airways is mandatory.
  • Attacks should be treated as early as possible.

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

continue to
Clinical Overview

Learn about the mechanism of action and therapy features in the clinical overview of Berinert.

Home About Berinert

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established.

BERINERT is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of BERINERT and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Appropriately trained patients may self-administer BERINERT upon recognition of an HAE attack. Advise patients to seek medical attention immediately following selfadministration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of BERINERT.

BERINERT is derived from human plasma. The risk of transmission of infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

BERINERT has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. In clinical trials, the half-life of BERINERT was shorter and clearance was faster in children than in adults; the clinical implication of this difference is not known.

Please see full prescribing information for BERINERT, including the patient product information.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d